Hubbry Logo
Chronic prostatitis/chronic pelvic pain syndromeChronic prostatitis/chronic pelvic pain syndromeMain
Open search
Chronic prostatitis/chronic pelvic pain syndrome
Community hub
Chronic prostatitis/chronic pelvic pain syndrome
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Chronic prostatitis/chronic pelvic pain syndrome
Chronic prostatitis/chronic pelvic pain syndrome
Chronic prostatitis/chronic pelvic pain syndrome
View on Wikipedia
from Wikipedia

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)
Other nameschronic nonbacterial prostatitis, prostatodynia, painful prostate
SpecialtyUrology
CausesUnknown[1]
Differential diagnosisBacterial prostatitis, benign prostatic hyperplasia, overactive bladder, cancer[2]
Frequency~4%[3]

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), previously known as chronic nonbacterial prostatitis, is long-term pelvic pain and lower urinary tract symptoms (LUTS) without evidence of a bacterial infection.[3] It affects about 2–6% of men.[3] Together with IC/BPS, it makes up urologic chronic pelvic pain syndrome (UCPPS).[4]

The cause is unknown.[1] Diagnosis involves ruling out other potential causes of the symptoms such as bacterial prostatitis, benign prostatic hyperplasia, overactive bladder, and cancer.[2][5]

Recommended treatments include multimodal therapy, physiotherapy, and a trial of alpha blocker medication or antibiotics in certain newly diagnosed cases.[6] Some evidence supports some non medication based treatments.[7]

Signs and symptoms

[edit]

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is characterized by pelvic or perineal pain without evidence of urinary tract infection,[8] lasting longer than 3 months,[9] as the key symptom. Symptoms may wax and wane. Pain can range from mild to debilitating. Pain may radiate to the back and rectum, making sitting uncomfortable. Pain can be present in the perineum, testicles, tip of penis, pubic or bladder area.[10] Dysuria, arthralgia, myalgia, unexplained fatigue, abdominal pain, constant burning pain in the penis, and frequency may all be present. Frequent urination and increased urgency may suggest interstitial cystitis (inflammation centred in bladder rather than prostate). Post-ejaculatory pain, mediated by nerves and muscles, is a hallmark of the condition.[11]

Cause

[edit]

The cause is unknown.[1] However, there are several theories of causation.

Pelvic floor dysfunction

[edit]

One theory is that CP/CPPS is a psychoneuromuscular (psychological, neurological, and muscular) disorder.[12] The theory proposes that anxiety or stress results in chronic, unconscious contraction of the pelvic floor muscles, leading to the formation of trigger points and pain.[12] The pain results in further anxiety and thus worsening of the condition.[12]

Nerves, stress and hormones

[edit]

Another proposal is that it may result from an interplay between psychological factors and dysfunction in the immune, neurological, and endocrine systems.[13]

A 2016 review suggested that although the peripheral nervous system is responsible for starting the condition, the central nervous system (CNS) is responsible for continuing the pain even without continuing input from the peripheral nerves.[14]

Theories behind the disease include stress-driven hypothalamic–pituitary–adrenal axis dysfunction and adrenocortical hormone (endocrine) abnormalities,[15][16][17] and neurogenic inflammation.[18][19][20]

The role of androgens is studied in CP/CPPS,[21] with C
21 11-oxygenated steroids (pregnanes) are presumed to be precursors to potent androgens.[15] Specifically, steroids like 11β-hydroxyprogesterone (11OHP4) and 11-ketoprogesterone (11KP4) can be converted to 11-ketodihydrotestosterone (11KDHT), an 11-oxo form of DHT with the same potency. The relationship between steroid serum levels and CP/CPPS suggests that deficiencies in the enzyme CYP21A2 may lead to increased biosynthesis of 11-oxo androgens and androgens biosynthesized via a backdoor pathway,[22] that contribute to the development of CP/CPPS. Non-classical congenital adrenal hyperplasia (CAH) resulting from CYP21A2 deficiency is typically considered asymptomatic in men. However, non-classical CAH could be a comorbidity associated with CP/CPPS.[23][16][17]

Bacterial infection

[edit]

The bacterial infection theory was shown to be unimportant in a 2003 study which found that people with and without the condition had equal counts of similar bacteria colonizing their prostates.[24][25]

Overlap with IC/PBS

[edit]

In 2007 the NIDDK began to group IC/PBS (Interstitial Cystitis & Painful Bladder Syndrome)and CP/CPPS under the umbrella term Urologic Chronic Pelvic Pain Syndromes (UCPPS). Therapies shown to be effective in treating IC/PBS, such as quercetin,[26] have also shown some efficacy in CP/CPPS.[27] Recent research has focused on genomic and proteomic aspects of the related conditions.[28]

People may experience pain with bladder filling, which is also a typical sign of IC.[29]

The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network has found that CPPS and bladder pain syndrome/interstitial cystitis (BPS/IC) are related conditions.[30]

UCPPS is a term adopted by the network to encompass both IC/BPS and CP/CPPS, which are proposed as related based on their similar symptom profiles. In addition to moving beyond traditional bladder- and prostate-specific research directions, MAPP Network scientists are investigating potential relationships between UCPPS and other chronic conditions that are sometimes seen in IC/PBS and CP/CPPS patients, such as irritable bowel syndrome, fibromyalgia, and chronic fatigue syndrome.

— The MAPP Network

Diagnosis

[edit]

There are no definitive diagnostic tests for CP/CPPS. It is a poorly understood disorder, even though it accounts for 90–95% of prostatitis diagnoses.[31] CP/CPPS may be inflammatory (Category IIIa) or non-inflammatory (Category IIIb), based on levels of pus cells in expressed prostatic secretions (EPS), but these subcategories are of limited use clinically. In the inflammatory form, urine, semen, and other fluids from the prostate contain pus cells (dead white blood cells or WBCs), whereas in the non-inflammatory form no pus cells are present. Recent studies have questioned the distinction between categories IIIa and IIIb, since both categories show evidence of inflammation if pus cells are ignored and other more subtle signs of inflammation, like cytokines, are measured.[32]

In 2006, Chinese researchers found that men with categories IIIa and IIIb both had significantly and similarly raised levels of anti-inflammatory cytokine TGFβ1 and pro-inflammatory cytokine IFN-γ in their EPS when compared with controls; therefore measurement of these cytokines could be used to diagnose category III prostatitis.[33] A 2010 study found that nerve growth factor could also be used as a biomarker of the condition.[34]

For CP/CPPS patients, analysis of urine and expressed prostatic secretions for leukocytes is debatable, especially due to the fact that the differentiation between patients with inflammatory and non-inflammatory subgroups of CP/CPPS is not useful.[35] Serum PSA tests, routine imaging of the prostate, and tests for Chlamydia trachomatis and Ureaplasma provide no benefit for the patient.[35]

Extraprostatic abdominal/pelvic tenderness is present in >50% of patients with chronic pelvic pain syndrome but only 7% of controls.[36] Healthy men have slightly more bacteria in their semen than men with CPPS.[37] The high prevalence of WBCs and positive bacterial cultures in the asymptomatic control population raises questions about the clinical usefulness of the standard Meares–Stamey four-glass test as a diagnostic tool in men with CP/CPPS.[37] By 2000, the use of the four-glass test by American urologists was rare, with only 4% using it regularly.[38]

Men with CP/CPPS are more likely than the general population to have Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)[39] and irritable bowel syndrome (IBS).

Experimental tests that could be useful in the future include tests to measure semen and prostate fluid cytokine levels. Various studies have shown increases in markers for inflammation such as elevated levels of cytokines,[40][41] myeloperoxidase,[42] and chemokines.[43]

Differential diagnosis

[edit]

Some conditions have similar symptoms to chronic prostatitis: bladder neck hypertrophy and urethral stricture may both cause similar symptoms through urinary reflux (inter alia) and can be excluded through flexible cystoscopy and urodynamic tests.[44][45][46]

Nomenclature

[edit]

A distinction is sometimes made between "IIIa" (Inflammatory) and "IIIb" (Noninflammatory) forms of CP/CPPS,[47] depending on whether pus cells (WBCs) can be found in the expressed prostatic secretions (EPS) of the patient. Some researchers have questioned the usefulness of this categorisation, calling for the Meares–Stamey four-glass test to be abandoned.[48]

In 2007, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) began using the umbrella term urologic chronic pelvic pain syndromes (UCPPS), for research purposes, to refer to pain syndromes associated with the bladder (i.e. interstitial cystitis/painful bladder syndrome, IC/PBS) and the prostate gland (i.e. chronic prostatitis/chronic pelvic pain syndrome, CP/CPPS).[49]

Older terms for this condition are "prostatodynia" (prostate pain) and non-bacterial chronic prostatitis. These terms are no longer in use.[50]

Symptom classification

[edit]

A classification system called "UPOINT" was developed by urologists Shoskes and Nickel to allow clinical profiling of a patient's symptoms into six broad categories:[51]

  • Urinary symptoms
  • Psychological dysfunction
  • Organ-specific symptoms
  • Infectious causes
  • Neurologic dysfunction
  • Tenderness of the pelvic floor muscles[52]

The UPOINT system allows for individualized and multimodal therapy.[53]

Treatment

[edit]

Chronic pelvic pain syndrome is difficult to treat.[54] Initial recommendations include education regarding the condition, stress management, and behavioral changes.[55]

Non-drug treatments

[edit]

Current guidelines by the European Association of Urology include:[56]

  • Pain education: conversation with the patient about pain, its causes and impact.
  • Physical therapy: some protocols focus on stretches to release overtensed muscles in the pelvic or anal area (commonly referred to as trigger points) including intrarectal digital massage of the pelvic floor, physical therapy to the pelvic area, and progressive relaxation therapy to reduce causative stress.[54] A device, that is typically placed in the rectum, has also been created for use together with relaxation.[57] This process has been called the Stanford protocol or the Wise-Anderson protocol.[57] The American Urological Association in 2014 listed manual physical therapy as a second line treatment.[55] Kegel exercises are not recommended.[55] Treatment may also include a program of "paradoxical relaxation" to prevent chronic tensing of the pelvic musculature.[12]
  • Psychological therapy: as most chronic pain conditions, psychotherapy might be helpful in its management regardless its direct impact on pain.[58][59]

Other non-drug treatments that have been evaluated for this condition include acupuncture, extracorporeal shockwave therapy, programs for physical activity, transrectal thermotherapy and a different set of recommendations regarding lifestyle changes.[7] Acupuncture probably leads to a decrease in prostatitis symptoms when compared with standard medical therapy but may not reduce sexual problems.[7] When compared with a simulated procedure, extracorporeal shockwave therapy also appears to be helpful in decreasing prostate symptoms without the impact of negative side effects but the decrease may only last while treatment is continued. As of 2018 use of extracorporeal shockwave therapy had been studied as a potential treatment for this condition in three small studies; there were short term improvements in symptoms and few adverse effects, but the medium terms results are unknown, and the results are difficult to generalize due to low quality of the studies.[7] Physical activity may slightly reduce physical symptoms of chronic prostatitis but may not reduce anxiety or depression. Transrectal thermotherapy, where heat is applied to the prostate and pelvic muscle area, on its own or combined with medical therapy may cause symptoms to decrease slightly when compared with medical therapy alone.[7] However, this method may lead to transient side effects. Alternative therapies like prostate massage or lifestyle modifications may or may not reduce symptoms of prostatitis.[7] Transurethral needle ablation of the prostate has been shown to be ineffective in trials.[60]

Neuromodulation has been explored as a potential treatment option for some time. Traditional spinal cord stimulation, also known as dorsal column stimulation has been inconsistent in treating pelvic pain: there is a high failure rate with these traditional systems due to the inability to affect all of the painful areas and there remains to be consensus on where the optimal location of the spinal cord this treatment should be aimed. As the innervation of the pelvic region is from the sacral nerve roots, previous treatments have been aimed at this region; however pain pathways seem to elude treatment solely directed at the level of the spinal cord (perhaps via the sympathetic nervous system) leading to failures.[61] Spinal cord stimulation aimed at the mid- to high-thoracic region of the spinal cord have produced some positive results. A newer form of spinal cord stimulation called dorsal root ganglion stimulation (DRG) has shown a great deal of promise for treating pelvic pain due to its ability to affect multiple parts of the nervous system simultaneously – it is particularly effective in patients with "known cause" (i.e. post surgical pain, endometriosis, pudendal neuralgia, etc.).[62][63]

Medications

[edit]

A number of medications can be used which need to be tailored to each person's needs and types of symptoms (according to UPOINTS, S = sexual: e.g. erectile dysfunction, ejaculatory dysfunction, postorgasmic pain).[56]

  • Treatment with antibiotics is controversial. A review from 2019 indicated that antibiotics may reduce symptoms. Some have found benefits in symptoms,[64][65] but others have questioned the utility of a trial of antibiotics.[66] Antibiotics are known to have anti-inflammatory properties and this has been suggested as an explanation for their partial efficacy in treating CPPS.[25] Antibiotics such as fluoroquinolones, tetracyclines and macrolides have direct anti-inflammatory properties in the absence of infection, blocking inflammatory chemical signals (cytokines) such as interleukin-1 (IL-1), interleukin-8 and tumor necrosis factor (TNF), which coincidentally are the same cytokines found to be elevated in the semen and EPS of men with chronic prostatitis.[67] The UPOINT diagnostic approach suggests that antibiotics are not recommended unless there is clear evidence of infection.[52]
  • The effectiveness of alpha blockers (tamsulosin, alfuzosin) is questionable in men with CPPS and may increase side effects like dizziness and low blood pressure.[64] A 2006 meta-analysis found that they are moderately beneficial when the duration of therapy was at least three months.[68]
  • An estrogen reabsorption inhibitor such as mepartricin improves voiding, reduces urological pain and improves quality of life in patients with chronic non-bacterial prostatitis.[69]
  • Phytotherapeutics such as quercetin and flower pollen extract have been studied in small clinical trials.[70][71] A 2019 review found that this type of therapy may reduce symptoms of CPPS without side effects, but may not improve sexual problems.[64]
  • 5-alpha reductase inhibitors probably help to reduce prostatitis symptoms in men with CPSS and don't appear to cause more side effects than when a placebo is taken.[64]
  • Anti-inflammatory drugs may reduce symptoms and may not lead to associated side effects.[64]
  • When injected into the prostate, Botulinum toxin A (BTA) may cause a large decrease in prostatitis symptoms. If BTA is applied to the muscles of the pelvis, it may not lead to the reduction of symptoms. For both of these procedures, there may be no associated side effects.[64]
  • For men with CPPS, taking allopurinol may give little or no difference in symptoms but also may not cause side effects.[64]
  • Traditional Chinese medicine may not lead to side effects and may reduce symptoms for men with CPPS. However, these medicines probably don't improve sexual problems or symptoms of anxiety and depression.[64]
  • Therapies that have not been properly evaluated in clinical trials although there is supportive anecdotal evidence include gabapentin, benzodiazepines and amitriptyline.[72]
  • Diazepam suppositories are a controversial treatment for CPPS – proponents believe that by delivering the medication in a closer proximity to the area of pain that better relief can be achieved. This has never been substantiated in any research and this hypothesis is invalid due to the fact that benzodiazepines act on the GABA receptor which is present in the central nervous system. This means that regardless of the route of administration (oral versus rectal/intra-vaginal), the drug will still need to travel to the central nervous system to work and is no more or less effective when given in this capacity. Research shows this method of delivery takes longer to achieve peak effect, lower bioavailability and lower peak serum plasma concentration.[73]

Emerging research

[edit]

In a preliminary 2005 open label study of 16 treatment-recalcitrant CPPS patients, controversial entities known as nanobacteria were proposed as a cause of prostatic calcifications found in some CPPS patients.[74] Patients were given EDTA (to dissolve the calcifications) and three months of tetracycline (a calcium-leaching antibiotic with anti-inflammatory effects,[75] used here to kill the "pathogens"), and half had significant improvement in symptoms. Scientists have expressed strong doubts about whether nanobacteria are living organisms,[76] and research in 2008 showed that "nanobacteria" are merely tiny lumps of abiotic limestone.[77][78]

The evidence supporting a viral cause of prostatitis and chronic pelvic pain syndrome is weak. Single case reports have implicated herpes simplex virus (HSV) and cytomegalovirus (CMV), but a study using PCR failed to demonstrate the presence of viral DNA in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer.[79] The reports implicating CMV must be interpreted with caution, because in all cases the patients were immunocompromised.[80][81][82] For HSV, the evidence is weaker still, and there is only one reported case, and the causative role of the virus was not proven,[83] and there are no reports of successful treatments using antiviral drugs such as aciclovir.

Due to the concomitant presence of bladder disorders, gastrointestinal disorders and mood disorders, research has been conducted to understand whether CP/CPPS might be caused by problems with the hypothetical bladder-gut-brain axis.[84]

Research has been conducted to understand how chronic bladder pain affects the brain, using techniques like MRI and functional MRI; as of 2016, it appeared that males with CP/CPPS have increased grey matter in the primary somatosensory cortex, the insular cortex and the anterior cingulate cortex and in the central nucleus of the amygdala; studies in rodents have shown that blocking the metabotropic glutamate receptor 5, which is expressed in the central nucleus of the amygdala, can block bladder pain.[14]

Prognosis

[edit]

In recent years, the prognosis for CP/CPPS has improved with the advent of multimodal treatment, phytotherapy, protocols aimed at quieting the pelvic nerves through myofascial trigger point release, anxiety control and chronic pain therapy.[85][86][87]

Epidemiology

[edit]

In the general population, chronic pelvic pain syndrome occurs in about 0.5% of men in a given year.[88] It is found in men of any age, with the peak incidence in men aged 35–45 years.[89] However, the overall prevalence of symptoms suggestive of CP/CPPS is 6.3%.[90] Further evidence suggests that the prevalence of CPPS-like symptoms in teenage males may be much higher than once suspected. However, this may not mean that CPPS is common in teenagers, as other conditions, such as sexually transmitted diseases, may be a more common cause of CPPS-like symptoms in this age group.[91]

The role of the prostate was questioned in the cause of CP/CPPS when both men and women in the general population were tested using the (1) National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI[92]) – with the female homologue of each male anatomical term used on questionnaires for female participants – (2) the International Prostate Symptom Score (IPSS), and (3) additional questions on pelvic pain. The prevalence of symptoms suggestive of CPPS in this selected population was 5.7% in women and 2.7% in men, placing in doubt the role of the prostate gland.[93]

Society and culture

[edit]

Notable cases have included:

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Chronic prostatitis/chronic pelvic pain syndrome

View on Grokipedia
from Grokipedia
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common and often debilitating urological condition in men characterized by persistent or recurrent pain in the pelvic, perineal, or genital region lasting at least three months, frequently accompanied by urinary symptoms such as frequency, urgency, or dysuria, and sometimes sexual dysfunction, without evidence of bacterial infection. It accounts for approximately 90% of all diagnosed cases of prostatitis and is classified by the National Institutes of Health (NIH) as category III prostatitis, subdivided into inflammatory (IIIA) and non-inflammatory (IIIB) subtypes based on the presence of white blood cells in prostatic secretions or semen. The primary symptom of CP/CPPS is chronic pain, which may localize to the lower abdomen, scrotum, penis, or lower back and can worsen with urination, ejaculation, or prolonged sitting; this pain often leads to significant psychological distress, including anxiety and depression. Unlike acute bacterial prostatitis, CP/CPPS typically lacks systemic signs like fever or chills, and symptoms can fluctuate in intensity over time. Epidemiologically, CP/CPPS affects 2-10% of men worldwide, with higher prevalence in those aged 30-50, and it is the most common urologic diagnosis in men under 50, resulting in about 2 million healthcare visits annually in the United States alone. Risk factors include prior urinary tract infections, nerve damage from surgery or trauma in the lower urinary tract, and psychological stress, though the condition can occur in men of any age. The etiology of CP/CPPS remains multifactorial and poorly understood, potentially involving neurogenic inflammation, autoimmune responses, pelvic floor muscle dysfunction, or prior non-bacterial infections, but no single cause has been definitively identified. Diagnosis relies on a detailed medical history, physical examination, and exclusion of other conditions through tests like the Meares-Stamey four-glass test, urinalysis, and prostate-specific antigen levels, rather than a single definitive marker. Management focuses on symptom relief through multimodal approaches, including alpha-blockers, anti-inflammatory drugs, physical therapy, and lifestyle modifications, as there is no cure.

Definition and classification

Nomenclature and terminology

The terminology surrounding chronic prostatitis underwent a significant evolution in the 1990s, transitioning from the broad label of "chronic prostatitis" to "chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)" to acknowledge that the condition's origins often extend beyond the prostate gland itself, involving multifocal pelvic pathology. This shift emphasized the non-infectious, symptom-driven nature of the disorder, moving away from assumptions of primary prostatic inflammation. The modern nomenclature was standardized by the National Institutes of Health (NIH) through a 1995 workshop on chronic prostatitis, which introduced a four-category classification system for prostatitis syndromes. CP/CPPS specifically corresponds to Category III, defined as a non-bacterial condition featuring chronic pelvic pain lasting at least three months without demonstrable infection in prostatic secretions or urine. This category is further subdivided into IIIA (inflammatory, with leukocytes in expressed prostatic secretions) and IIIB (non-inflammatory, without such findings), though both share the core clinical presentation of persistent pain. More recent guidelines, such as the 2025 European Association of Urology (EAU) guidelines on chronic pelvic pain, have further evolved the terminology by introducing "Primary Prostate Pain Syndrome (PPPS)" for cases without proven infection or obvious pathology. PPPS is defined by persistent or recurrent pain reproducible by prostate palpation, often with lower urinary tract and sexual symptoms, and aligns with ICD-11 criteria for Chronic Primary Pain, emphasizing a central nervous system-involved pain model over organ-specific focus. CP/CPPS is distinctly differentiated from other prostatitis types: acute bacterial prostatitis (Category I) involves abrupt onset with systemic symptoms such as high fever, chills, and urinary retention due to acute infection, often requiring hospitalization. In contrast, asymptomatic inflammatory prostatitis (Category IV) is incidentally detected through elevated inflammatory markers in prostatic fluid during evaluations for other conditions, without any associated pain or urinary symptoms. The term "syndrome" in CP/CPPS reflects its heterogeneous clinical manifestations and lack of a unified pathophysiological mechanism, encompassing a spectrum of pain, urinary, and sexual dysfunctions driven by potential contributors like pelvic floor dysfunction, neurogenic inflammation, and psychosocial stress, rather than a singular disease entity.

Symptom-based categories

The National Institutes of Health (NIH) classification system for prostatitis syndromes, established through a 1999 consensus report from the NIH International Prostatitis Collaborative Network, categorizes chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) as category III, distinguishing it from acute bacterial (category I) and chronic bacterial (category II) forms. Categories I and II are excluded in CP/CPPS diagnosis through negative bacterial cultures from urine and prostatic secretions, confirming the absence of identifiable pathogens. Within category III, CP/CPPS is further subdivided into IIIA (inflammatory) and IIIB (non-inflammatory) based on the presence or absence of white blood cells (WBCs) in expressed prostatic secretions (EPS) or post-prostatic massage urine (VB3), typically assessed via the Meares-Stamey four-glass test or its variants. In IIIA, elevated WBCs indicate an inflammatory component without demonstrable infection, while IIIB shows no significant WBC elevation, suggesting non-inflammatory mechanisms. This subclassification, introduced in the late 1990s, relies on microscopic examination where ≥10 WBCs per high-power field in EPS or VB3 supports the inflammatory designation. The rationale for these symptom-based categories is to standardize initial clinical evaluation and research by differentiating potential inflammatory processes from non-inflammatory ones, facilitating targeted diagnostic steps like prostatic massage fluid analysis. However, the utility is limited by significant symptom overlap between IIIA and IIIB, as both present with similar pelvic pain and voiding issues, and the inflammatory marker does not consistently predict treatment response or etiology. Studies from the NIH Chronic Prostatitis Collaborative Research Network have highlighted that this binary split often fails to capture the heterogeneous nature of CP/CPPS, leading to challenges in patient stratification. Over time, recognition of these limitations has driven evolution toward multidimensional phenotyping approaches beyond the NIH categories, aiming for more precise patient subgrouping and tailored therapies. For instance, systems like UPOINT, developed in 2008, integrate multiple domains to address the syndrome's complexity, marking a shift from inflammation-focused classification to comprehensive symptom profiling.

Phenotyping systems

The UPOINT phenotyping system, developed to subclassify patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) for tailored management, evaluates six clinical domains: Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, and Tenderness. Each domain is assessed through patient history, validated questionnaires like the NIH Chronic Prostatitis Symptom Index (NIH-CPSI), and physical examination, such as digital rectal exam for pelvic tenderness, resulting in a binary positive/negative classification per domain to guide phenotype-directed therapy. Unlike the NIH categories, which primarily distinguish inflammatory from non-inflammatory subtypes, UPOINT addresses the multifactorial nature of CP/CPPS by incorporating broader aspects like psychosocial factors and tenderness, enabling more precise hypothesis testing for etiology and intervention. Validation studies have demonstrated that the number of positive UPOINT domains correlates with greater symptom severity, as measured by higher NIH-CPSI scores (r = 0.706, p < 0.001 in a cohort of 371 Chinese patients) and reduced quality of life. In a prospective European study of 110 men, UPOINT-guided multimodal therapy led to a significant reduction in positive domains (from 3.9 ± 0.9 to 1.75 ± 0.74, p = 0.022) and NIH-CPSI total scores (from 29.8 ± 6.1 to 13.9 ± 2.8, p = 0.025), indicating improved treatment response tied to phenotypic targeting. These findings have been replicated across diverse populations, including North American and Asian cohorts, supporting UPOINT's utility in correlating phenotypes with clinical outcomes. While effective for stratification, UPOINT is not intended as a diagnostic tool but rather as a prognostic framework to identify candidates for specific interventions, with limitations including its reliance on subjective reporting and lack of standardization in some domains across studies.

Signs and symptoms

Pain manifestations

Chronic pelvic pain lasting at least three months is the hallmark symptom of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), typically manifesting as discomfort in the perineal, suprapubic, or genital regions, including pulling or tugging sensations in the urethra outside of urination. This pain may also involve the penis, scrotum, testes, lower back, or abdomen, with approximately 70% of patients reporting discomfort extending beyond the pelvis, potentially linked to pelvic floor tension or neurogenic factors. The condition is defined by persistent or recurrent pain in these areas, often interfering with daily activities and quality of life. Pain patterns in CP/CPPS vary, ranging from constant aching to episodic flares that wax and wane over time. Exacerbations commonly occur with prolonged sitting, urination, or ejaculation, while some relief may follow voiding. These patterns can include sharp, burning, or throbbing sensations, with intensity fluctuating based on triggers. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quantifies pain through its dedicated subdomain, which sums scores from items assessing pain or discomfort in four locations (0-4), during urination and ejaculation (0-2), frequency of pain (0-5), and average pain severity (0-10), for a total pain score of 0-21. This tool helps assess the multidimensional impact of pain, contributing to an overall index score of 0-43 that includes urinary and quality-of-life domains. In CP/CPPS, pain often exhibits both nociceptive and neuropathic characteristics, though neuropathic features predominate in many cases due to central sensitization. Nociceptive pain is typically described as localized aching or throbbing from tissue irritation, whereas neuropathic pain involves burning, tingling, or heightened sensitivity, often linked to genital tenderness and altered heat pain thresholds in the perineum. Studies indicate that about 8% of patients show predominantly neuropathic mechanisms, associated with more severe genitourinary symptoms, while mixed patterns involving sensitization contribute to treatment resistance.

Urinary and sexual symptoms

Patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) frequently experience lower urinary tract symptoms (LUTS), including dysuria (painful urination), urgency (sudden need to urinate, which can manifest as an immediate urge triggered by drinking liquids, reflecting an overactive bladder-like state due to prostate inflammation irritating the bladder or associated pelvic floor muscle tension), frequency (increased urination episodes), weak stream (reduced urine flow), hesitancy (difficulty initiating urination), and nocturia (waking at night to urinate). These symptoms often overlap with those of benign prostatic hyperplasia (BPH), such as obstructive and irritative voiding issues, but CP/CPPS is distinguished by its chronic duration (at least three months) and prominent pelvic pain component, whereas BPH typically lacks persistent pain. LUTS in CP/CPPS may be exacerbated by associated pelvic pain, contributing to overall symptom burden. Sexual dysfunction is a common comorbidity in CP/CPPS, affecting a substantial proportion of patients and often linked to pelvic floor muscle tension. Specific manifestations include ejaculatory pain, decreased libido, and erectile difficulties, with studies reporting overall sexual dysfunction in 92% of affected men, ejaculatory pain in 56%, decreased libido in 66%, and erectile dysfunction or ejaculatory difficulties in 31% each. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) provides a validated tool for quantifying urinary and quality-of-life impacts in CP/CPPS. Its urinary symptoms subdomain (items 5 and 6) scores incomplete bladder emptying (0-5) and urination frequency (0-5), yielding a total of 0-10, while the quality-of-life subdomain (items 7-9) assesses symptom interference with daily activities, social functioning, and overall well-being on a 0-12 scale. These subdomains help clinicians track symptom severity and treatment response without relying on exhaustive numerical benchmarks.

Associated systemic features

Patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) commonly exhibit psychological comorbidities, including anxiety and depression, with up to 60% meeting diagnostic criteria for major depressive disorder and as many as 78% reporting symptoms of depression. Anxiety disorders, including panic disorder, are also significantly more common in patients with CP/CPPS than in controls. Catastrophizing, characterized by exaggerated negative orientation toward pain, is common and associated with heightened emotional distress and poorer symptom management. Systemic features in CP/CPPS often stem from central sensitization, a process of amplified neural signaling that extends pain processing beyond the pelvic region and contributes to widespread hypersensitivity. Fatigue affects many patients, with chronic fatigue syndrome diagnosed in approximately 3% and linked to overall symptom severity. Myalgias are common, occurring in conjunction with fibromyalgia in about 4% of individuals, while irritable bowel symptoms manifest in up to 22%, reflecting shared pathways in overlapping chronic pain conditions. These associated features profoundly impact quality of life, with sleep disturbances reported more frequently in patients experiencing multisite pain and correlating with greater non-pelvic symptom burden. Reduced work productivity is also evident, as assessed by validated instruments such as the NIH Chronic Prostatitis Symptom Index quality-of-life domain, which captures limitations in daily activities and overall functioning. Bidirectional relationships exist between psychosocial stress and CP/CPPS manifestations, wherein stress exacerbates symptoms like pain and fatigue, though without implying direct causality.

Pathophysiology

Pelvic floor and muscular dysfunction

Pelvic floor hypertonicity, characterized by excessive tension in the muscles supporting the pelvic organs, plays a central role in the pathogenesis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This condition often involves key muscles such as the levator ani and obturator internus, which exhibit elevated resting tone and impaired relaxation during physical examination. Such hypertonicity can lead to the development of myofascial trigger points—tender, hyperirritable nodules within taut muscle bands that refer pain to surrounding areas, exacerbating the chronic pain experienced in CP/CPPS. The hypertonic state contributes to a self-perpetuating cycle of pain by promoting muscle spasms that compress nearby nerves and blood vessels, thereby irritating neural structures like the pudendal nerve and restricting vascular flow to the pelvic region. This mechanical compression intensifies nociceptive signaling and local ischemia, further tightening the muscles in a protective guarding response that sustains the dysfunction. Physical examinations of CP/CPPS patients frequently reveal this elevated resting tone, with studies reporting it in approximately 70% of cases, particularly among those with ejaculation-related pain. Additionally, pelvic floor hypertonicity can impair normal voiding mechanics by causing functional outlet obstruction, where failure to relax the muscles during urination leads to hesitancy, straining, and incomplete bladder emptying. This contributes to the urinary symptoms commonly associated with CP/CPPS, distinguishing it from primary prostatic issues. Stress may briefly exacerbate this muscle tension, though its mechanisms are addressed elsewhere.

Neuroendocrine and stress mechanisms

Central sensitization plays a pivotal role in the amplification of pain signals in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), where chronic nociceptive input leads to heightened responsiveness in the central nervous system. This process involves hyperexcitability of dorsal horn neurons in the spinal cord and altered activity in brain regions such as the insula, as evidenced by functional MRI studies showing hyperactivity in pain-processing areas. In clinical assessments using thermal algometry, men with CP/CPPS demonstrated significantly increased sensitivity to noxious heat stimuli in the perineal region compared to controls (mean peak visual analog scale scores higher in patients, p<0.05), indicating localized central pain sensitization without similar changes in non-pelvic areas like the thigh. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis contributes to symptom persistence in CP/CPPS through chronic stress responses that alter neuroendocrine homeostasis. Men with CP/CPPS exhibit elevated awakening cortisol responses compared to healthy controls (mean slope 0.85 μg/dL vs. 0.59 μg/dL, p<0.05), correlating with higher self-reported stress and anxiety levels as measured by the Brief Symptom Inventory (global severity index at 93rd percentile vs. 48th percentile, p<0.0001). This HPA hyperactivity may exacerbate pain flares by enhancing neural plasticity and lowering pain thresholds, independent of peripheral factors. Autonomic nervous system imbalance, particularly sympathetic overdrive, underlies visceral hypersensitivity and contributes to the multisystem symptoms of CP/CPPS. Heart rate variability analyses reveal reduced high-frequency power (indicating parasympathetic underactivity) and elevated low-frequency/high-frequency ratios (suggesting sympathetic dominance) in affected patients compared to controls (p<0.001 for high-frequency differences). These alterations manifest as exaggerated cardiovascular and pelvic responses to stress, with blood pressure variability studies confirming dampened parasympathetic recovery in men with CP/CPPS (p<0.05 vs. controls). Neurotransmitters such as substance P and glutamate drive neurogenic pain mechanisms in CP/CPPS by facilitating central and peripheral sensitization. Substance P, released from C-fiber afferents, binds to NK-1 receptors to amplify nociceptive signaling and promote dorsal horn excitability, while glutamate acts via NMDA receptor upregulation to sustain long-term potentiation of pain pathways. In preclinical models, blocking these transmitters with agents like pregabalin reduces hyperalgesia by inhibiting their release from voltage-sensitive calcium channels, highlighting their role in persistent pelvic pain.

Inflammatory and infectious pathways

In chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), low-grade inflammation is a prominent feature, characterized by the presence of inflammatory cells such as lymphocytes and macrophages in prostatic tissue, even in cases lacking detectable bacterial infection. Studies have identified elevated levels of pro-inflammatory cytokines, including interleukin-6 (IL-6) and interleukin-8 (IL-8), in expressed prostatic secretions and seminal plasma of patients with both inflammatory (category IIIA) and non-inflammatory (category IIIB) subtypes of CP/CPPS. These cytokines contribute to localized tissue damage and pain sensitization, with IL-8 particularly associated with neutrophil recruitment and persistent inflammation in the prostate. Infectious pathways play a role in some CP/CPPS cases through persistent, low-virulence bacterial infections that evade conventional detection. Uropathogenic Escherichia coli (UPEC), a common culprit, forms biofilms within the prostate that protect bacteria from antibiotics and host defenses, leading to chronic inflammation. These biofilms rely on quorum sensing mechanisms, where bacteria communicate via signaling molecules to coordinate biofilm formation and persistence, explaining negative culture results despite ongoing infection. Similar biofilm-associated infections have been observed with other pathogens like Pseudomonas aeruginosa, whose quorum sensing systems exacerbate inflammation in prostatitis models. Autoimmune hypotheses propose that CP/CPPS may arise from an aberrant immune response targeting prostate-specific antigens. Molecular mimicry, where microbial antigens resemble self-proteins in the prostate, can trigger cross-reactive T-cell and antibody responses, leading to chronic inflammation. Experimental autoimmune prostatitis models in rodents demonstrate this mechanism, with immunization against prostate antigens inducing pelvic pain and inflammatory infiltrates similar to human CP/CPPS. Post-infectious autoimmunity often follows an acute bacterial prostatitis episode, where initial infection breaks immune tolerance and initiates a self-sustaining autoimmune process. In such cases, lingering immune activation against prostate tissue persists after bacterial clearance, contributing to ongoing symptoms in CP/CPPS. This pathway highlights the transition from acute infection to chronic non-bacterial inflammation observed in many patients.

Microbiome dysbiosis

Recent studies utilizing 16S rRNA sequencing have revealed significant alterations in the prostate and gut microbiomes of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) compared to healthy controls. In the prostate and seminal fluid microbiomes, there is a notable reduction in the abundance of Lactobacillus species, alongside an increase in the Firmicutes phylum, as observed in analyses from 2024 cohorts. Similarly, gut microbiome profiling in 2025 investigations demonstrates decreased alpha-diversity and shifts in bacterial composition, with elevated Firmicutes and diminished protective taxa in CP/CPPS cases. These microbiome dysbioses contribute to CP/CPPS pathophysiology by promoting inflammation through mechanisms such as leaky gut, where impaired intestinal barrier integrity permits bacterial translocation and endotoxin release into the circulation, exacerbating pelvic inflammation. Additionally, dysbiosis may facilitate ascending infections from the gut or urogenital tract, linking microbial imbalances to persistent immune activation in the prostate microenvironment. This extends prior understandings of infectious pathways by highlighting specific ecological shifts in microbial communities. Further evidence from 16S rRNA metagenomic studies correlates microbiome composition with CP/CPPS symptom severity, including pelvic pain and urinary dysfunction scores. For example, reduced Lactobacillus levels and elevated pro-inflammatory taxa associate with higher expression of biomarkers like S100A12, a calcium-binding protein that amplifies neurogenic inflammation and pain signaling in affected tissues. These findings underscore the role of microbial dysbiosis in modulating inflammatory cascades relevant to disease progression. Microbiome-targeted approaches hold potential for alleviating CP/CPPS by restoring eubiosis, thereby enhancing gut barrier function and reducing inflammatory metabolite production to mitigate downstream pelvic pain and immune dysregulation.

Causes and risk factors

Non-infectious etiologies

Non-infectious etiologies of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) encompass a range of mechanical, lifestyle-related, neurological, and genetic factors that contribute to the development or exacerbation of symptoms without involving bacterial pathogens. These triggers often involve disruption of pelvic floor dynamics, nerve function, or inflammatory signaling pathways, leading to persistent pain and dysfunction. Research indicates that such factors can initiate a cycle of central sensitization and muscle tension in susceptible individuals. A history of pelvic trauma or surgery is recognized as a significant risk factor for CP/CPPS, potentially through mechanisms like nerve damage or scarring that impair pelvic tissue integrity. For instance, injuries from accidents or prior urological procedures may lead to altered prostate drainage or heightened pain sensitivity in the region. Clinical observations suggest that individuals with such histories are at elevated risk, though exact quantification varies across studies. Lifestyle factors, including prolonged sitting, cycling, dehydration, and smoking, can promote urinary stasis and increased perineal pressure, thereby aggravating pelvic floor tension and symptom severity in CP/CPPS. Extended periods of sitting compress the pudendal nerve and perineal structures, while cycling on narrow seats exacerbates this pressure, potentially leading to ischemic pain. Dehydration concentrates urine, irritating the prostate and bladder, and contributes to incomplete emptying that fosters local inflammation. Smoking is linked to increased inflammation in the prostate. Recommendations to mitigate these include ergonomic adjustments, adequate hydration, and smoking cessation to reduce stasis. Anatomical factors such as phimosis, prostatic calculi, and incomplete bladder emptying may also contribute to non-infectious CP/CPPS by promoting urinary stasis and local irritation. Neurological insults, such as prior herpes zoster infection or pudendal nerve entrapment, play a key role in non-infectious CP/CPPS by inducing neuropathic pain through direct nerve irritation or post-viral damage. Herpes zoster in sacral dermatomes can result in postherpetic neuralgia manifesting as chronic pelvic discomfort, while pudendal nerve entrapment—often from repetitive strain—causes burning pain worsened by sitting. These conditions overlap with CP/CPPS presentations and may be misdiagnosed without targeted evaluation. Although genetic factors have been investigated, studies have not identified definitive polymorphisms associated with increased susceptibility to CP/CPPS. Stress may act as a modulator in these etiologies by amplifying neuroendocrine responses that heighten pain perception in CP/CPPS.

Infectious contributors

Infectious contributors to chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) primarily involve persistent or low-grade microbial infections that may evade standard detection methods, leading to ongoing pelvic discomfort. Bacterial pathogens, particularly fastidious organisms, have been implicated in a subset of cases through chronic low-level bacteriuria. For instance, Chlamydia trachomatis has been detected in prostatic secretions or urine of approximately 5-10% of men with CP/CPPS symptoms, often contributing to subtle, non-acute inflammation without overt systemic signs. This organism's intracellular nature allows it to persist in prostatic tissue, potentially triggering localized immune responses that perpetuate pain cycles. Viral persistence in prostatic tissue represents another infectious pathway, with certain viruses linked to sustained inflammation in CP/CPPS. Human papillomavirus (HPV), particularly high-risk strains, has been identified in prostate biopsies of men with chronic prostatitis, where it may promote epithelial changes and inflammatory cascades. These viral elements are thought to integrate into host cells, fostering a microenvironment conducive to prolonged pelvic pain, though the association remains debated. Post-infectious mechanisms further highlight how resolved urinary tract infections (UTIs) can evolve into CP/CPPS through immune dysregulation. Following bacterial clearance from an acute UTI, residual neurogenic inflammation and altered sensory signaling in the bladder and prostate can manifest as persistent pelvic pain, often mediated by pathways like TRPV1 sensitization. This syndrome is characterized by heightened chemokine responses, such as MCP-1/CCR2 axis activation, which sustains central pain processing even after the initial infection subsides. Certain behavioral and procedural risk factors elevate susceptibility to these infectious contributors. Unprotected anal intercourse increases exposure to sexually transmitted pathogens like Chlamydia trachomatis and HPV, facilitating their ascent into prostatic ducts via urethral contamination. Indwelling urinary catheterization, commonly used in hospitalized or urologically compromised patients, introduces bacteria or disrupts mucosal barriers, heightening the risk of ascending infections that seed chronic prostatitis.

Overlaps with comorbid conditions

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) frequently overlaps with interstitial cystitis/bladder pain syndrome (IC/BPS), with studies indicating that approximately 17% of men who meet high-specificity criteria for one condition also fulfill criteria for the other. This overlap manifests in shared pelvic pain and urinary symptoms, such as urgency and frequency, and is supported by common pathophysiological features including mast cell activation, which promotes local inflammation and nociceptor sensitization in the bladder and prostate regions. Increased mast cell degranulation and tryptase release have been observed in prostatic secretions from CP/CPPS patients, paralleling findings in IC/BPS bladder biopsies. CP/CPPS also shows comorbidity with irritable bowel syndrome (IBS), where individuals with CP/CPPS have a significantly higher likelihood of a prior IBS diagnosis, with an adjusted odds ratio of 2.46. This association arises from shared visceral hypersensitivity, involving altered signaling in the enteric nervous system that amplifies pain responses to distension or inflammation in pelvic organs. Mechanisms such as corticotropin-releasing factor (CRF) modulation of submucosal neurons and mast cell-mediated peripheral sensitization contribute to this cross-organ hypersensitivity, linking gastrointestinal and urogenital symptoms. An overlap exists between CP/CPPS and chronic fatigue syndrome (CFS), with CP/CPPS patients reporting CFS symptoms more than twice as often as age-matched controls (2.2% versus 0.8%). This comorbidity is attributed to common abnormalities in central pain processing, including hypothalamic-pituitary-adrenal axis dysregulation and amplified neural responses in brain regions like the paraventricular nucleus, which heighten overall pain perception and fatigue. These overlaps pose diagnostic challenges, as symptoms from comorbid conditions can reinforce each other bidirectionally through central and peripheral cross-sensitization, complicating attribution without a unified underlying etiology. For instance, visceral pain from one syndrome may exacerbate urinary symptoms in CP/CPPS via shared neural pathways, leading to delayed or misdiagnosis.

Diagnosis

Clinical history and examination

The diagnosis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) begins with a thorough clinical history to establish the chronic nature of symptoms and rule out acute or alternative conditions. Patients typically report persistent or recurrent pelvic pain or discomfort lasting at least three months within the preceding six months, often localized to the perineum, suprapubic area, genitals, or lower back, with potential triggers such as sitting, ejaculation, or physical activity. A detailed inquiry into prior urogenital infections, trauma, surgeries, or sexually transmitted infections is essential, as these may contribute to symptom onset or exacerbation. Standardized tools like the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) are recommended to quantify symptom severity, including pain domains (e.g., location and intensity), urinary symptoms (e.g., frequency and urgency), and impact on quality of life, facilitating objective tracking and phenotyping. Physical examination focuses on identifying localized tenderness and musculoskeletal contributions without invasive testing at this stage. A digital rectal examination (DRE) is performed to assess prostate size, consistency, and tenderness upon palpation, which may reproduce the patient's pain and support a diagnosis of CP/CPPS if no masses or irregularities are noted. Concurrent evaluation of the pelvic floor muscles via transrectal or external palpation is crucial to detect myofascial trigger points, hypertonicity, or dysfunction, common in many cases and often indicating the need for targeted therapy. Examination of the external genitalia, abdomen, and lower spine should screen for any evident abnormalities, such as scrotal swelling or orthopedic issues, while a general assessment includes vital signs to identify systemic involvement. Red flags in the history or examination, such as unexplained fever, significant unintentional weight loss, hematuria, or neurological deficits, warrant urgent evaluation to exclude serious pathologies like infection, malignancy, or spinal disorders. These findings prompt immediate referral for further investigation rather than presuming CP/CPPS. A multidisciplinary approach enhances initial assessment, involving collaboration among urologists, pelvic floor physical therapists, and sometimes physiatrists or psychologists to address the multifaceted nature of symptoms, including psychosocial factors like anxiety or depression that may amplify pain perception. This comprehensive intake ensures tailored management from the outset, with brief reference to established symptom categories—such as urogenital pain, lower urinary tract symptoms, and sexual dysfunction—for contextualizing patient reports.

Laboratory and imaging tests

Laboratory tests play a supportive role in confirming or ruling out infectious components in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), particularly through urinalysis and cultures. A key procedure involves prostatic massage followed by analysis of the post-massage urine (often termed VB3 in the four-glass test or the second urine sample in the two-glass test), which collects prostate fluid to detect leukocytes indicating inflammation or bacteria suggesting chronic bacterial prostatitis. This test helps differentiate inflammatory from non-inflammatory subtypes, with positive bacterial cultures in the post-massage sample supporting a diagnosis of chronic bacterial prostatitis when initial voided urine is sterile. Prostate-specific antigen (PSA) levels are typically measured as part of the evaluation, though they are often normal in CP/CPPS; elevations above 4 ng/mL can occur due to inflammation and may necessitate further imaging to exclude prostate cancer. Successful treatment of underlying inflammation with antibiotics or anti-inflammatory agents can normalize elevated PSA levels in many cases, reducing the need for invasive follow-up. In one study of patients with CP/CPPS, PSA exceeded 4 ng/mL in approximately 10% of cases, highlighting its limited specificity but utility in guiding additional testing. Imaging modalities such as transrectal ultrasound (TRUS) and magnetic resonance imaging (MRI) are employed to identify structural abnormalities in the prostate, including cysts and calcifications, which may contribute to symptoms in a subset of patients. TRUS can visualize prostatic calcifications, often seen as hyperechoic foci with posterior shadowing, and simple cysts as anechoic structures, aiding in the assessment of potential obstructive or irritative factors. MRI provides superior soft-tissue contrast to detect these features, such as T2-hyperintense cysts or signal voids from calcifications, particularly in multiparametric protocols, though calcifications may be challenging to delineate without specialized sequences. Advanced diagnostic tools like cystoscopy and electromyography (EMG) offer further insights when initial tests are inconclusive, particularly for evaluating bladder neck involvement or neuromuscular dysfunction. Cystoscopy allows direct visualization of the prostatic urethra and bladder to identify mucosal abnormalities or overlaps with conditions like interstitial cystitis, performed outpatient with local anesthesia. Pelvic floor EMG assesses nerve and muscle function, revealing abnormalities in about half of CP/CPPS patients, such as increased resting tone, but it is not recommended as a primary diagnostic substitute due to its variable sensitivity.

Differential diagnosis

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) must be differentiated from other conditions that present with overlapping pelvic pain, urinary symptoms, and discomfort to prevent misdiagnosis. Prostate cancer is a critical consideration, especially in men over 50 years of age, where it can mimic CP/CPPS through nonspecific pelvic discomfort; it is distinguished by an abnormal digital rectal examination (DRE) showing prostatic nodules, induration, or asymmetry, along with elevated prostate-specific antigen (PSA) levels greater than 4 ng/mL. Further evaluation with multiparametric MRI or biopsy is warranted if these findings are present. Urethral stricture or calculi represent another important mimic, often causing obstructive urinary symptoms that overlap with CP/CPPS; these are identified via uroflowmetry, which reveals a reduced maximum flow rate (typically <15 mL/s) and a prolonged, plateau-shaped flow curve indicative of obstruction. Confirmatory tests such as cystoscopy or retrograde urethrography can visualize the narrowing or stones. Pudendal neuralgia, a neuropathic condition involving entrapment of the pudendal nerve, can produce perineal pain similar to CP/CPPS but is differentiated by focal, pinpoint tenderness on targeted physical examination (e.g., at the ischial spine) and pain worsened by prolonged sitting or Valsalva maneuvers, in contrast to the diffuse, non-positional pelvic pain characteristic of CP/CPPS. Diagnostic nerve blocks providing temporary relief further support this distinction. The cornerstone of accurate diagnosis is a systematic algorithm that prioritizes excluding malignancy and infection before labeling CP/CPPS, incorporating history, DRE, urinalysis, PSA testing (ideally delayed 4-6 weeks post-any acute infection), and selective imaging or endoscopy based on red flags such as hematuria or abnormal flow rates. Test results from laboratory and imaging evaluations, such as negative cultures or normal PSA, help confirm the noninfectious, nonmalignant nature of CP/CPPS.

Treatment

Non-pharmacological interventions

Pelvic floor physical therapy represents a cornerstone non-pharmacological intervention for managing chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), particularly in cases involving pelvic floor dysfunction. This therapy typically includes techniques such as myofascial trigger point release to alleviate muscle tension and biofeedback to facilitate muscle relaxation and coordination. Specific exercises recommended include Kegel exercises, involving contracting and relaxing the pelvic floor muscles, and reverse Kegels, focusing on relaxation to address muscle spasms and nocturia. Warm sitz baths for 15-20 minutes in the evening are also advised to relax the pelvic area. A randomized controlled trial demonstrated that myofascial physical therapy resulted in a 57% global response rate for symptom improvement among men with CP/CPPS, compared to 21% with global therapeutic massage, highlighting its targeted efficacy in reducing pain and urinary symptoms. Biofeedback-assisted training further supports pelvic floor relaxation; a case report described multimodal physical therapy including biofeedback leading to substantial improvements in pain and quality of life in individual patients with CP/CPPS. Lifestyle modifications play a supportive role in symptom management for CP/CPPS by addressing contributing factors such as stress and hydration status. Adequate hydration helps maintain urinary tract health and prevents concentration of irritants, while stress reduction techniques like yoga and mindfulness practices can mitigate the exacerbation of pelvic pain through autonomic nervous system modulation. For instance, an intervention involving yoga postures and breathing exercises led to significant reductions in pain intensity and enhancements in quality of life among patients with chronic pelvic pain. Mindfulness-based approaches, including meditation, have been shown to alter pain perception and decrease associated anxiety, offering accessible tools for daily self-management. Dietary advice focuses on avoiding bladder irritants to control symptoms in CP/CPPS, as certain foods and beverages can heighten pelvic discomfort and urinary urgency. Common recommendations include limiting caffeine and alcohol, which are known to exacerbate symptoms by irritating the bladder lining and increasing detrusor activity. A survey of CP/CPPS patients identified coffee, alcoholic beverages, and spicy foods as frequent triggers for symptom worsening, with avoidance leading to notable relief in many cases. These modifications, often integrated into broader lifestyle changes, promote sustained symptom control without invasive measures. Psychological support, particularly cognitive behavioral therapy (CBT), aids in pain coping for individuals with CP/CPPS by addressing maladaptive thoughts and behaviors that amplify suffering. CBT techniques, such as cognitive restructuring and relaxation training, help patients develop adaptive strategies to manage chronic pain and improve daily functioning. Meta-analyses indicate that CBT significantly enhances pain reduction, well-being, and activity levels compared to usual care, with conditional endorsements from clinical guidelines for its adjunctive use. This approach is especially beneficial for those with overlapping psychological distress, fostering long-term resilience.

Pharmacological options

Pharmacological management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) primarily targets symptom relief, as no curative therapy exists for this non-bacterial condition. Treatments are often selected based on patient phenotype, such as the UPOINTS classification system, to address specific domains like urinary symptoms or pain. Evidence supports several classes of medications, though efficacy is generally modest and best achieved in multimodal approaches. Alpha-blockers, such as tamsulosin, work by relaxing prostate and bladder neck smooth muscle to alleviate voiding dysfunction. They are recommended for patients with prominent lower urinary tract symptoms, particularly those with disease duration less than one year. A Cochrane systematic review of 18 randomized controlled trials involving 1,524 participants found low- to very low-quality evidence that alpha-blockers reduce NIH Chronic Prostatitis Symptom Index (NIH-CPSI) total scores by a mean difference of -5.01 points (95% CI: -7.41 to -2.61) in the short term, with improvements in pain, urinary, and quality-of-life subscores. Response rates approximate 50% in eligible patients, though benefits diminish in long-standing CP/CPPS. The European Association of Urology (EAU) guidelines endorse their use (LE 1a), typically at doses like tamsulosin 0.4 mg daily. Adverse effects include increased risk of ejaculation disorders (RR 1.60, 95% CI: 1.09-2.34). Anti-inflammatory agents aim to reduce elevated cytokine levels and pelvic inflammation, particularly in the inflammatory subtype (NIH Category IIIA). Nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib or nimesulide, provide short-term pain relief and are conditionally recommended as part of multimodal therapy. A meta-analysis indicates NSAIDs increase favorable response rates by 80% compared to placebo. The bioflavonoid quercetin, with antioxidant and anti-inflammatory properties, is suggested for symptom management at 500 mg twice daily. In a double-blind, placebo-controlled trial of 30 men with Category III CP/CPPS, quercetin led to significant NIH-CPSI improvement with end scores of 13.1 compared to 18.8 for placebo (p=0.003), with 67% of participants showing at least 25% symptom improvement. The American Urological Association (AUA) rates this evidence as Grade B, cautioning against long-term NSAID use due to gastrointestinal risks. For inflammatory CP/CPPS, empirical antibiotics may be considered in treatment-naïve patients despite negative cultures, targeting potential occult infection. Fluoroquinolones, such as ciprofloxacin or levofloxacin, are preferred for their prostate penetration. EAU guidelines recommend a course of at least 6 weeks for early-onset cases (<1 year), with a network meta-analysis showing modest improvements in pain, voiding, and quality of life (RR 1.4, 95% CI: 1.1-1.8). A randomized trial supported quinolone efficacy in reducing symptoms even without proven bacterial etiology. However, AUA guidelines advise against routine use in culture-negative cases (Clinical Principle), limiting to a short trial if no response to other therapies, due to lack of sustained benefit and resistance concerns. Tricyclic antidepressants like amitriptyline address neuropathic components of pelvic pain at low doses (10-25 mg nightly), modulating central pain pathways without requiring depressive symptoms. They are conditionally recommended for persistent pain (AUA Grade C; EAU LE 1b). In chronic pelvic pain cohorts, amitriptyline alone or combined with gabapentin outperformed placebo, reducing pain scores and improving function in approximately 50% of responders. A systematic review of urological pelvic pain supports their role, extrapolated from interstitial cystitis data where low-dose amitriptyline yielded sustained relief in long-term use. Side effects like drowsiness may limit adherence, necessitating dose titration.

Interventional and surgical approaches

For patients with refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) who do not respond to conservative or pharmacological treatments, interventional procedures targeting neural or muscular components offer targeted relief, particularly when pelvic floor dysfunction contributes to symptoms. These approaches are typically considered after multidisciplinary evaluation, with nerve blocks serving as both diagnostic and therapeutic tools to confirm pudendal neuralgia or related entrapment. Pudendal nerve blocks involve injecting local anesthetics, often with corticosteroids, via transperineal, transrectal, or transgluteal approaches to interrupt pain signals from the pudendal nerve, which innervates the pelvic floor and perineum. In a cohort of men with CP/CPPS, pudendal blocks provided significant short-term pain reduction, with up to 70% reporting at least 50% improvement in visual analog scale scores lasting 4-6 weeks. Similarly, ganglion impar blocks, targeting the sympathetic ganglion at the sacrococcygeal junction, are used for visceral perineal pain in CP/CPPS, delivering relief through a trans-sacrococcygeal needle placement; case series indicate 60-80% of patients experience reduced coccydynia-like symptoms for 3-6 months post-injection. These blocks are minimally invasive, office-based procedures with low complication rates, including transient numbness or infection risk under 5%. Botulinum toxin type A (Botox) injections into the pelvic floor muscles aim to reduce hypertonicity and spasm, which exacerbate pain in CP/CPPS subtypes with myofascial involvement. Administered under electromyography guidance at trigger points like the levator ani, doses of 100-200 units have shown efficacy in randomized trials, with 40-60% of refractory patients reporting moderate to marked symptom improvement on the National Institutes of Health Chronic Prostatitis Symptom Index, sustained for 3-6 months before potential repeat dosing. A systematic review confirmed Botox's role in inhibiting nociceptive signaling, though benefits are subtype-specific and not universal, with side effects limited to temporary urinary retention in 10-15% of cases. Transurethral microwave thermotherapy (TUMT) delivers microwave energy via a urethral catheter to heat prostatic tissue, reducing inflammation and organ-specific symptoms in select CP/CPPS cases, particularly inflammatory subtype IIIA. In prospective studies, cooled TUMT sessions (30-60 minutes, 45-50°C target temperature) yielded durable pain relief, with approximately two-thirds of patients achieving at least 50% reduction in pelvic pain scores at 6-12 months follow-up, alongside improved urinary flow. This outpatient procedure is well-tolerated, with adverse events like transient hematuria or dysuria occurring in under 20%, and is reserved for those with prostatic congestion unresponsive to other therapies. Surgical interventions, such as pudendal nerve decompression, are rarely indicated and limited to confirmed entrapment via prior positive nerve blocks, addressing compressive fibrosis in Alcock's canal. Laparoscopic or transperineal approaches release the nerve from surrounding ligaments, with series reporting 70-80% of patients experiencing over 50% pain reduction at 1-year follow-up, though long-term data are sparse and complication rates include wound infection (5-10%). The American Urological Association guidelines classify this as a conditional option for refractory pudendal neuralgia in CP/CPPS, emphasizing multidisciplinary input due to variable outcomes and irreversibility.

Emerging therapies

Recent research has focused on microbiome modulation as a novel approach for managing chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), particularly targeting dysbiosis linked to persistent inflammation. Urovaxom, an oral immunostimulant derived from lysates of 18 Escherichia coli strains, has shown promise in clinical trials. In a 2025 multicenter study involving patients with CPPS following radical prostatectomy, Urovaxom administration led to significant improvements in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, especially in pain and quality-of-life domains, with reduced symptom recurrence compared to controls. This therapy enhances immune response against uropathogens, potentially addressing subtle microbial imbalances without broad-spectrum antibiotics. Acupuncture has emerged as a non-pharmacological neuromodulatory intervention effective for refractory CP/CPPS cases, alleviating pain through central and peripheral mechanisms. A 2025 narrative review synthesized evidence indicating that acupuncture, including variants like electroacupuncture and moxibustion, provides individualized symptom relief by modulating neural pathways, reducing inflammation, and improving urinary function in patients unresponsive to conventional treatments. Another 2025 meta-analysis of randomized controlled trials reported significantly higher response rates and lower NIH-CPSI scores with acupuncture versus sham or drug controls, with minimal adverse effects and sustained benefits up to six months post-treatment. These findings support its integration into multimodal strategies for pain-dominant phenotypes. Pharmacological innovations emphasize targeted drug combinations to achieve synergistic effects beyond monotherapy limitations. This approach highlights the value of multimodal pharmacotherapy, as endorsed in updated guidelines, for enhancing symptom relief in complex cases. Biomarker-guided therapies represent a precision medicine frontier, with S100A12 identified as a key indicator of neuroinflammation in CP/CPPS. A 2025 study in the Journal of Pain analyzed prostatic fluid and serum samples, finding elevated S100A12 levels strongly correlated with pain severity and inflammatory markers, enabling stratification of patients for anti-inflammatory interventions like selective inhibitors. High S100A12 expression predicted better responses to targeted therapies, such as IL-1 receptor antagonists, suggesting potential for personalized treatment algorithms to optimize outcomes and minimize trial-and-error prescribing. As of 2025, the AUA and EAU guidelines recommend UPOINTS phenotyping to guide multimodal therapy, prioritizing non-pharmacological interventions and cautioning against routine antibiotics in non-bacterial cases.

Prognosis

Short-term outcomes

Short-term outcomes in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) primarily focus on symptom relief achieved through multimodal therapies, such as combinations of alpha-blockers, anti-inflammatories, and physical therapy, within the initial 3-6 months of treatment. Many clinical studies report partial symptom improvement in a majority of patients, defined as a clinically meaningful reduction of at least 6 points on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). For instance, a prospective study of phenotype-guided multimodal treatment demonstrated a mean NIH-CPSI reduction of 8.21 points after 3 months, with 66.2% of participants achieving this threshold for partial relief. Similarly, another trial using antibiotics, alpha-blockers, and anti-inflammatories found 77.5% of patients experiencing comparable improvement in total NIH-CPSI scores over a short-term follow-up period. Complete remission, characterized by full resolution of symptoms and return to baseline function, is uncommon during this timeframe, as supported by clinical guidelines emphasizing the chronic nature of the condition. Flares, or acute exacerbations of pelvic pain and urinary symptoms, remain common even with initial response, often requiring targeted short-term interventions like anti-inflammatories or other non-opioid analgesics for breakthrough management; opioids may be considered in refractory cases with caution. Monitoring progress typically involves serial assessments using the NIH-CPSI, a validated tool responsive to changes in pain, urinary symptoms, and quality of life domains over 3-6 months.

Long-term management challenges

One of the primary challenges in managing chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) over the long term is the high frequency of symptom relapse, with recurrence rates reaching up to 50% in older patients following initial treatment. This relapse complicates sustained remission and necessitates repeated interventions that can strain healthcare resources and patient adherence. The unpredictable nature of these recurrences underscores the need for vigilant monitoring, as symptoms such as pelvic pain and urinary dysfunction may re-emerge despite multimodal therapies, contributing to cycles of frustration and incomplete recovery. The psychological burden associated with CP/CPPS significantly exacerbates long-term management difficulties, with patients experiencing heightened levels of depression, anxiety, and reduced quality of life; some studies report suicidal ideation in up to 5% of cases, similar to other chronic pain conditions. Additionally, the persistent pain and functional limitations often result in disability claims, as recognized by systems like the U.S. Department of Veterans Affairs, where chronic prostatitis qualifies for ratings up to 40% based on symptom severity and impact on daily activities. These mental health challenges not only amplify the perceived intensity of pelvic and systemic symptoms but also hinder engagement with treatment, perpetuating a vicious cycle of emotional distress and physical deconditioning. As of the 2025 AUA guideline update, addressing these issues requires a multidisciplinary approach to ensure sustainable outcomes, incorporating ongoing physiotherapy to alleviate pelvic floor tension and psychological support such as cognitive-behavioral therapy to mitigate emotional strain. Collaboration among urologists, physical therapists, and mental health professionals is essential for tailoring interventions that address both physical and psychosocial aspects, promoting long-term symptom control and preventing isolation or burnout. Prognosis varies by patient phenotype, comorbidities, and adherence to management. Patient education plays a crucial role in empowering individuals with CP/CPPS for self-management, focusing on strategies like regular exercise, stress reduction techniques, and recognition of early relapse signs to avoid deconditioning and maintain functional independence. By fostering understanding of the condition's chronicity and the benefits of lifestyle modifications, education enhances treatment adherence and reduces reliance on acute care, ultimately improving quality of life despite ongoing challenges.

Epidemiology

Prevalence and incidence

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects a significant portion of the male population, with prevalence estimates ranging from 2% to 10% worldwide, particularly among men aged 20 to 50 years. This condition is one of the most common urological diagnoses in men under 50, accounting for a substantial burden in primary care and specialty settings. Lifetime prevalence of CP/CPPS symptoms can reach up to 16%, reflecting the chronic nature of the disorder and its potential for recurrence over decades. Annual incidence rates in primary care are estimated at approximately 0.5% (5 cases per 1,000 person-years), with studies reporting around 4.9 new cases per 1,000 men per year in community-based populations. Geographic variations influence reported rates, with higher prevalence observed in some Asian populations; for instance, a large-scale survey in China found 8.4% of men reporting prostatitis-like symptoms. Underreporting is prevalent due to social stigma surrounding pelvic pain and urological issues.

Demographic and risk patterns

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) predominantly affects men in their middle years, with the highest incidence observed between the ages of 30 and 50 years. It is the most common urological diagnosis among men younger than 50, representing up to 8-14% of urology office visits in this group. The condition is rare in adolescents under 20 and less frequent in men over 70, though incidence may rise modestly around age 60 due to overlapping conditions like benign prostatic hyperplasia. Demographically, CP/CPPS occurs across all ethnic groups without significant racial disparities, as prevalence rates are comparable in African American and Caucasian populations. It is more prevalent among sedentary males, particularly those in urban settings with lifestyles involving prolonged sitting, such as office workers, where reduced physical activity correlates with higher symptom severity. Building on overall prevalence estimates of 2-16% in the general male population, these patterns highlight environmental and lifestyle influences over genetic factors. Key risk factors include smoking, which elevates the odds of pain severity by approximately 1.5 times through pro-inflammatory effects on prostate tissue. Prior sexually transmitted infections (STIs), such as chlamydia, increase susceptibility by facilitating chronic inflammation, particularly in cases involving unprotected sexual activity. Occupational or habitual prolonged sitting exacerbates risks by promoting pelvic congestion and muscle tension, potentially intensifying symptoms in susceptible individuals. Comorbidities are common, with anxiety disorders affecting around 32% of patients, contributing to symptom perpetuation via heightened stress responses. Up to 40% of individuals with CP/CPPS experience co-occurring affective disorders, underscoring the interplay between psychological factors and pelvic pain. These associations emphasize the need for holistic screening in affected populations.

History and guidelines

Historical perspectives

The recognition of chronic prostatitis dates back to the 19th century, when symptoms such as pelvic pain and urinary difficulties were often attributed to nervous disorders of the prostate. This perspective reflected the limited diagnostic tools of the era, where chronic cases were frequently linked to hysteria or neurosis rather than organic pathology. In the 20th century, understanding shifted significantly through organized efforts to reclassify the condition beyond psychogenic explanations. The 1995 National Institutes of Health (NIH) Workshop on Chronic Prostatitis represented a pivotal moment, redefining nonbacterial forms as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), emphasizing pain as the central feature and establishing a standardized categorization system (NIH categories I-IV) to facilitate research and treatment. This was followed by the formation of the NIH Chronic Prostatitis Collaborative Research Network in 1999, which further advanced diagnostic and therapeutic studies. This redefinition moved away from earlier dismissals of symptoms as purely functional, validating CP/CPPS as a distinct urological entity with multifactorial origins. Key milestones in the evolution of CP/CPPS management included the development of the UPOINT phenotyping system in 2009 by Shoskes and Nickel, which categorizes patients based on urinary, psychosocial, organ-specific, infectious, neurological/systemic, and tenderness domains to guide multimodal therapy. In the 2010s, recognition of the prostate and gut microbiome's role emerged as a major advance, with studies identifying dysbiosis in urine and stool samples correlated to symptom severity and inflammation, challenging the notion of CP/CPPS as noninfectious. Seminal work, such as Mazzoli et al.'s 2010 investigation into biofilms in prostatic calcifications, highlighted persistent bacterial communities as potential contributors. Historically, CP/CPPS carried significant stigma, often dismissed as psychosomatic or neurotic, leading to patient frustration and inadequate care, as evidenced by mid-20th-century literature labeling it a "psychosomatic incidence." The NIH reclassification and subsequent research have transformed this view, establishing CP/CPPS as a validated chronic condition warranting interdisciplinary approaches, reducing dismissal and improving patient outcomes.

Current clinical guidelines

The 2025 American Urological Association (AUA) guidelines on the diagnosis and management of male chronic pelvic pain emphasize a phenotype-driven approach using the UPOINT classification system to tailor multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), integrating pharmacological, physical, and psychological interventions based on individual symptom domains such as urinary, psychosocial, and organ-specific factors. Routine or repeated antibiotic therapy is not recommended for CP/CPPS in the absence of confirmed bacterial infection, as it lacks supporting evidence and may contribute to resistance. Alpha-blockers, such as tamsulosin or alfuzosin, receive a moderate recommendation (Evidence Level: Grade B) for patients with voiding symptoms, based on randomized controlled trials (RCTs) demonstrating improvements in pain, urinary flow, and quality of life. Phytotherapy options, including quercetin, pollen extracts (e.g., Cernilton), and saw palmetto, are conditionally recommended (Evidence Level: Grade B) in the AUA guidelines for symptom relief, with RCTs showing reductions in National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores compared to placebo, though benefits are more pronounced in early-stage disease. The guidelines advocate a multidisciplinary framework, potentially incorporating pelvic floor physical therapy and low-intensity extracorporeal shockwave therapy (Evidence Level: Grade A), to address the heterogeneous nature of CP/CPPS. The 2025 European Association of Urology (EAU) guidelines on chronic pelvic pain similarly endorse a multimodal, multidisciplinary strategy for CP/CPPS, classified as chronic primary prostate pain syndrome, prioritizing non-invasive therapies and patient education within a biopsychosocial model. Alpha-blockers are strongly recommended (Evidence Level: 1a/2a) for symptom management, particularly in cases of less than one year duration, with meta-analyses indicating a relative risk of 1.4 for overall improvement in pain and voiding symptoms. Phytotherapy, such as pollen extracts and quercetin, is supported by strong evidence (Level 1a/1b), showing significant NIH-CPSI reductions and fewer adverse events than alternatives like ibuprofen. Acupuncture is strongly recommended in the EAU guidelines (Evidence Level: 1a/1b) for CP/CPPS, with systematic reviews and RCTs demonstrating sustained pain reduction and quality-of-life improvements over sham treatments at 24-week follow-ups. Microbiome assessment is not routinely advised, though the guidelines note modest benefits from targeted antimicrobials in select inflammatory phenotypes, aligning with a non-antibiotic-first approach. Both AUA and EAU frameworks utilize GRADE methodology, rating alpha-blockers as strong/moderate based on high-quality RCTs, while phytotherapy receives conditional/strong ratings from moderate evidence. Recent updates include exploration of the S100A12 protein as a potential biomarker, with a 2025 study showing elevated serum levels correlating with inflammatory (type IIIA) and pain symptoms in young CP/CPPS patients, suggesting neuroimmune interactions via RAGE signaling that could aid future phenotyping, though it is not yet incorporated into clinical guidelines. A 2025 systematic review of RCTs on drug combinations for chronic pelvic pain, including CP/CPPS, found limited high-quality evidence supporting superior efficacy over monotherapies, such as tadalafil plus alpha-blockers, highlighting the need for further trials to validate multimodal pharmacotherapy.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK599550/
  2. https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/prostatitis-inflammation-prostate
  3. https://www.mayoclinic.org/diseases-conditions/prostatitis/symptoms-causes/syc-20355766
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2684227/
  5. https://pubmed.ncbi.nlm.nih.gov/8911515/
  6. https://pubmed.ncbi.nlm.nih.gov/10411041/
  7. https://uroweb.org/guidelines/chronic-pelvic-pain
  8. https://pubmed.ncbi.nlm.nih.gov/10443716/
  9. https://www.auanet.org/guidelines-and-quality/guidelines/male-chronic-pelvic-pain
  10. https://icurology.org/DOIx.php?id=10.4111/kju.2014.55.4.276
  11. https://www.sciencedirect.com/science/article/abs/pii/S0090429599002058
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC4316954/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC2829842/
  14. https://link.springer.com/article/10.1007/s11918-009-0019-5
  15. https://pubmed.ncbi.nlm.nih.gov/19118880/
  16. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052044
  17. https://journals.sagepub.com/doi/10.1177/1756287219857271
  18. https://bestpractice.bmj.com/topics/en-us/3000324
  19. https://www.auajournals.org/doi/10.1097/01.ju.0000082710.47402.03
  20. https://www.sciencedirect.com/science/article/pii/S1526590022003017
  21. https://www.aafp.org/pubs/afp/issues/2016/0215/p290.html
  22. https://my.clevelandclinic.org/health/diseases/15319-prostatitis
  23. https://pubmed.ncbi.nlm.nih.gov/16952676/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3713242/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6800057/
  26. https://pubmed.ncbi.nlm.nih.gov/28373134/
  27. https://doi.org/10.1093/ptj/pzac059
  28. https://doi.org/10.1007/s11934-025-01290-4
  29. https://www.auajournals.org/doi/10.1097/JU.0000000000004564
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC10782122/
  31. https://doi.org/10.1016/j.juro.2007.10.084
  32. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2022.903250/full
  33. https://doi.org/10.1016/j.juro.2007.01.144
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC2837110/
  35. https://www.nature.com/articles/srep28608
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3591463/
  37. https://journals.lww.com/ajandrology/fulltext/2024/26010/comparison_of_cytokine_levels_in_prostatic.11.aspx
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3028831/
  39. https://www.mdpi.com/2076-0817/5/4/65
  40. https://pubmed.ncbi.nlm.nih.gov/19460822/
  41. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2007.01971.x
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11087208/
  43. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00898/full
  44. https://www.nature.com/articles/s41598-017-09751-8
  45. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1488732/full
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC12270845/
  47. https://www.sciencedirect.com/science/article/pii/S2405844024143332
  48. https://pubmed.ncbi.nlm.nih.gov/40914239/
  49. https://jmhg.springeropen.com/articles/10.1186/s43042-024-00540-3
  50. https://www.physio-pedia.com/Chronic_Pelvic_Pain_Syndrome_-_Male
  51. https://www.verywellhealth.com/pudendal-neuralgia-chronic-pelvic-pain-2564631
  52. https://ainsworthinstitute.com/conditions/pelvic-pain/
  53. https://www.ncbi.nlm.nih.gov/books/NBK562246/
  54. https://pubmed.ncbi.nlm.nih.gov/19297275/
  55. https://onlinelibrary.wiley.com/doi/10.1111/j.1439-0272.2009.01033.x
  56. https://icurology.org/DOIx.php?id=10.4111/kju.2013.54.2.73
  57. https://infectagentscancer.biomedcentral.com/articles/10.1186/s13027-020-00305-8
  58. https://www.nature.com/articles/s41598-018-24056-0
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4552327/
  60. https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostatitis
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC3894747/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4893514/
  63. https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/chronic-prostatitis-chronic-pelvic-pain-syndrome
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4880941/
  65. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2018.00002/full
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC2957306/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC8915637/
  68. https://www.mayoclinic.org/diseases-conditions/prostatitis/diagnosis-treatment/drc-20355771
  69. https://emedicine.medscape.com/article/437745-workup
  70. https://pubmed.ncbi.nlm.nih.gov/16442595/
  71. https://radiopaedia.org/articles/prostatitis?lang=us
  72. https://insightsimaging.springeropen.com/articles/10.1186/s13244-021-01024-3
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC8492071/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC11947716/
  75. https://pubmed.ncbi.nlm.nih.gov/37276301/
  76. https://pubmed.ncbi.nlm.nih.gov/16753385/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC12528306/
  78. https://pubmed.ncbi.nlm.nih.gov/19539268/
  79. https://academic.oup.com/ptj/article/90/12/1795/2737819
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5225749/
  81. https://www.pthealth.ca/blog/how-mindfulness-practice-can-help-manage-pelvic-pain/
  82. https://www.sciencedirect.com/science/article/abs/pii/S0090429513008546
  83. https://www.ichelp.org/diet-choices-and-lifestyle-factors-implicated-in-men-with-chronic-pelvic-pain/
  84. https://www.auajournals.org/doi/10.1097/JU.0000000000003847
  85. https://pubmed.ncbi.nlm.nih.gov/35938980/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC6040620/
  87. https://journals.sagepub.com/doi/10.1177/22840265251340366
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC2884216/
  89. https://my.clevelandclinic.org/health/treatments/24917-pudendal-nerve-block
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC6832516/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC8780260/
  92. https://www.cochrane.org/evidence/CD012552_intervention-treating-chronic-prostatitis-and-chronic-pelvic-pain-men
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC2245867/
  94. https://www.urologytimes.com/view/tumt-shows-durable-results-chronic-prostatitis
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC5566848/
  96. https://www.ncbi.nlm.nih.gov/books/NBK544272/
  97. https://www.europeanurology.com/article/S0302-2838%2804%2900462-2/fulltext
  98. https://euti.org/journal/view.php?number=434
  99. https://www.euti.org/upload/pdf/uti-2550014007.pdf
  100. https://jclinque.com/article/acupuncture-for-chronic-prostatitis-chronic-pelvic-pain-syndrome-a-narrative-review-of-therapeutic-techniques-and-mechanisms
  101. https://journals.sagepub.com/doi/10.1177/15579883241290035
  102. https://www.auajournals.org/doi/10.1097/JU.0000000000004565
  103. https://www.sciencedirect.com/science/article/pii/S1526590025007631
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC4756547/
  105. https://www.sciencedirect.com/science/article/pii/S0090429522003478
  106. https://www.auajournals.org/doi/10.1097/JU.0000000000003820
  107. https://www.sciencedirect.com/science/article/pii/S0014299919303802
  108. https://series.publisso.de/index.php/de/publisso_gold/publishing/books/overview/52/2
  109. https://www.va.gov/vetapp21/Files3/21013643.txt
  110. https://pubmed.ncbi.nlm.nih.gov/12521579/
  111. https://pubmed.ncbi.nlm.nih.gov/38261706/
  112. https://pubmed.ncbi.nlm.nih.gov/17341178/
  113. https://www.urologytimes.com/view/chronic-prostatitis-called-common-condition-american-men
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC2292121/
  115. https://pubmed.ncbi.nlm.nih.gov/19524948/
  116. https://www.liebertpub.com/doi/10.1089/jomh.2013.0015
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC5494351/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC3857999/
  119. https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.20846
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC7542966/
  121. https://www.sciencedirect.com/science/article/abs/pii/S0022399916306237
  122. https://jamanetwork.com/journals/jama/fullarticle/289053
  123. https://journalofethics.ama-assn.org/article/prostatitis-prevalence-classification-and-treatment/2006-11
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC5300850/
  125. https://academic.oup.com/femspd/article/59/3/337/496586
  126. https://pubmed.ncbi.nlm.nih.gov/5146341/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC3921839/
  128. https://www.auanet.org/documents/Guidelines/PDF/2025%20Guidelines/CPP%20Unabridged%20041025.pdf
  129. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Chronic-Pelvic-Pain-2025.pdf
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC12169960/
Add your contribution
Related Hubs
User Avatar
No comments yet.